Jean Mack predicts GAIN's IND will be cleared by the FDA within weeks and Phase 2 will begin in Q3 2026
“over the next couple of weeks, we expect, our IND to be, opened by the FDA. And then our phase two study will begin in earnest, next quarter, in the third quarter”
→ Read the source episode
Our resolution criterion
disputableFDA clears GAIN's IND application and Phase 2 study initiates in Q3 2026 (by September 30, 2026)
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Laurent Levy predicts Nanobiotics will complete pancreatic, melanoma, and esophageal cancer trials before H1 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.